What is the Reshape Lifesciences Inc. stock price forecast?

Reshape Lifesciences Inc. is currently trading at $2.26. View real-time AI analysis on Alpha Lenz.

What is Reshape Lifesciences Inc. insider trading activity?

View the latest insider trading data for Reshape Lifesciences Inc. on Alpha Lenz.

What is Reshape Lifesciences Inc.'s P/E ratio?

Reshape Lifesciences Inc.'s P/E ratio is -0.0.

Reshape Lifesciences Inc.

NASDAQ · RSLS

$2.26-0.04(-1.74%)Pre-market

Ask about Reshape Lifesciences Inc.'s future dividend policy...

Alpha Chat Insight

“Reshape Lifesciences Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -222.5%.”

Ask for details →

Company Overview

Reshape Lifesciences Inc. is a biotechnology company specializing in the development and commercialization of transformative technologies for the treatment of obesity and metabolic diseases. The company focuses on creating medical devices and solutions that provide minimally invasive weight loss options, thereby improving the quality of life for patients with metabolic conditions. Reshape Lifesciences is known for its innovative product portfolio, including the Lap-Band Adjustable Gastric Banding System, which offers a less invasive alternative for obesity treatment compared to traditional bariatric surgery. The company’s efforts primarily impact the healthcare and medical device industries, striving to meet the demands of rising global obesity rates. Headquartered in San Clemente, California, Reshape Lifesciences continues to contribute to the medical sector by advancing healthcare solutions that emphasize patient safety, efficacy, and long-term health benefits, thus playing a vital role in addressing one of today's most prevalent health challenges.

CEOMr. Paul F. Hickey

Websitehttps://www.reshapelifesciences.com

SectorHealthcare

IndustryMedical Devices

Employees17

Company Statistics

FY 2024

Profile

$46.61KMarket Cap

$8.01MRevenue

0.00Shares Out

17Employees

Margins

63.17%Gross

-75.14%EBITDA

-83.29%Operating

-88.57%Pre-Tax

-89.06%Net

Valuation

-0.01P/E

-0.18P/B

0.01EV/Sales

-0.05EV/EBITDA

-0.01P/FCF

Growth (CAGR)

-16.19%Rev 3Yr

-11.90%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-92.26%ROA

-222.46%ROE

-86.28%ROIC

Financial Health

$693.00KCash & Cash Equivalents

$4.35MNet Debt

-1994.47%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Reshape Lifesciences Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -222.5%.”

Ask for details →

Frequently Asked Questions

Reshape Lifesciences Inc. (ticker: RSLS) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 17 employees. Market cap is $46,606.

The current price is $2.26 with a P/E ratio of -0.01x and P/B of -0.18x.

ROE is -222.46% and operating margin is -83.29%. Annual revenue is $8M.